# Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-use-of-histopathology-and-its-associated-methodologies-to-support-biomarker-qualification-guidance-for-industry/9f893e7b-4aa3-4e4f-81bb-b2d74e521f3e

> FDA guidance document: Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry. Issue date: May 16, 2016. Get complete insights and analysis.

---

## Details

- Title: Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2016-05-16
- Last Changed: 2020-05-07
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2011-D-0872">FDA-2011-D-0872</a>

## Related Documents

- [Determining Whether to Submit an ANDA or a 505(b)(2) Application](https://www.globalkeysolutions.net/guidances/guidance-document/determining-whether-to-submit-an-anda-or-a-505b2-application/c04d36f1-c78a-4aaf-8e45-6a99420cf632)
- [Botanical Drug Development: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/botanical-drug-development-guidance-for-industry/bec78068-96c3-424e-b070-7b4ecfcfc8bf)
- [Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-related-considerations-for-low-molecular-weight-heparin-guidance-for-industry/3f5ab3c9-bcf6-4c53-bf06-2133ec436dd8)